Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CKS1B | P61024 | 2/20 | 0.47 |
| ▸ | SKP1 | P63208 | 2/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623060 | 1.00 | MAPT (0.49) | MAPTCKS1BSKP1SKP2ATM | |
| SCHEMBL1623466 | 1.00 | MAPT (0.49) | MAPTCKS1BSKP1SKP2ATM | |
| SCHEMBL1622919 | 0.90 | MAPT (0.49) | MAPTCKS1BSKP1SKP2ATM | |
| SCHEMBL21804799 | 0.85 | MAPT (0.46) | MAPTCKS1BSKP1SKP2ATM | |
| SCHEMBL1623136 | 0.80 | MAPT (0.52) | MAPTCKS1BSKP1SKP2GPR119 | |
| SCHEMBL12719901 | 0.75 | MAPT (0.47) | MAPTCKS1BSKP1SKP2GPR119 | |
| SCHEMBL12719902 | 0.74 | MAPT (0.53) | MAPTCKS1BSKP1SKP2GPR119 | |
| SCHEMBL13568074 | 0.73 | CKS1B (0.49) | MAPTCKS1BSKP1SKP2GPR119 | |
| SCHEMBL21041387 | 0.73 | MAPT (0.49) | MAPTCKS1BSKP1SKP2GPR119 | |
| SCHEMBL21042225 | 0.73 | MAPT (0.52) | MAPTCKS1BSKP1SKP2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928099-B2 | Pyrimido [4,5-D] azepine derivatives as 5-HT2c agonists | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | ANDREWS MARK | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | HTR2C, HTR2A, HTR5A | MAPT 4054/4885CKS1B 1899/4885SKP1 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.